Advanced

N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants

Sandberg, K; Fellman, Vineta LU ; Stigson, L; Thiringer, K and Hjalmarson, O (2004) In Biology of the Neonate 86(4). p.275-279
Abstract
Oxygen toxicity is thought to be an important factor involved in development of bronchopulmonary dysplasia (BPD) in the very preterm infant. Glutathione (GSH) plays a major role in the antioxidant defense system in the preterm lung and there are theoretical implications that N-acetylcysteine (NAC) treatment could improve its function. The purpose of this study was to investigate whether NAC treatment during the first week of life to preterm infants improved neonatal lung function as a measure of lung injury. The study was part of a multi-center Nordic controlled trial with prophylactic intravenous NAC treatment (16-32 mg/kg/day) for 6 days in newborn infants with birth weights 500-999 g. Lung mechanics, with calculations of compliance and... (More)
Oxygen toxicity is thought to be an important factor involved in development of bronchopulmonary dysplasia (BPD) in the very preterm infant. Glutathione (GSH) plays a major role in the antioxidant defense system in the preterm lung and there are theoretical implications that N-acetylcysteine (NAC) treatment could improve its function. The purpose of this study was to investigate whether NAC treatment during the first week of life to preterm infants improved neonatal lung function as a measure of lung injury. The study was part of a multi-center Nordic controlled trial with prophylactic intravenous NAC treatment (16-32 mg/kg/day) for 6 days in newborn infants with birth weights 500-999 g. Lung mechanics, with calculations of compliance and resistance of the respiratory system, together with measurements of functional residual capacity and indices of gas mixing efficiency in the lung, were performed in 33 preterm infants (18 received NAC and 15 placebo) before discharge from the NICU. Median (range) gestational age was 25 (24-28) weeks in the NAC-treated infants and 25 (24-29) in the placebo group. Corresponding mean (SD) birth weights were 0.774 (0.11) and 0.761 (0.12) kg respectively. Lung function measurements did not show any significant differences between NAC-treated infants compared to placebo when examined before discharge from the NICU. We conclude that prophylactic NAC treatment to extremely low birth weight infants during the first week of life does not improve lung function at term. Copyright (C) 2004 S. Karger AG, Basel. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
lung function testing, in preterm infants, NAC treatment, N-acetylcysteine treatment, antioxidant defense system, bronchopulmonary dysplasia
in
Biology of the Neonate
volume
86
issue
4
pages
275 - 279
publisher
Karger
external identifiers
  • pmid:15297790
  • wos:000225100900011
  • scopus:8344247129
ISSN
1421-9727
DOI
10.1159/000080089
language
English
LU publication?
yes
id
a9197fce-0c42-4b66-b081-1a33f9c53a3a (old id 261064)
date added to LUP
2007-10-31 12:03:51
date last changed
2017-11-28 14:50:34
@article{a9197fce-0c42-4b66-b081-1a33f9c53a3a,
  abstract     = {Oxygen toxicity is thought to be an important factor involved in development of bronchopulmonary dysplasia (BPD) in the very preterm infant. Glutathione (GSH) plays a major role in the antioxidant defense system in the preterm lung and there are theoretical implications that N-acetylcysteine (NAC) treatment could improve its function. The purpose of this study was to investigate whether NAC treatment during the first week of life to preterm infants improved neonatal lung function as a measure of lung injury. The study was part of a multi-center Nordic controlled trial with prophylactic intravenous NAC treatment (16-32 mg/kg/day) for 6 days in newborn infants with birth weights 500-999 g. Lung mechanics, with calculations of compliance and resistance of the respiratory system, together with measurements of functional residual capacity and indices of gas mixing efficiency in the lung, were performed in 33 preterm infants (18 received NAC and 15 placebo) before discharge from the NICU. Median (range) gestational age was 25 (24-28) weeks in the NAC-treated infants and 25 (24-29) in the placebo group. Corresponding mean (SD) birth weights were 0.774 (0.11) and 0.761 (0.12) kg respectively. Lung function measurements did not show any significant differences between NAC-treated infants compared to placebo when examined before discharge from the NICU. We conclude that prophylactic NAC treatment to extremely low birth weight infants during the first week of life does not improve lung function at term. Copyright (C) 2004 S. Karger AG, Basel.},
  author       = {Sandberg, K and Fellman, Vineta and Stigson, L and Thiringer, K and Hjalmarson, O},
  issn         = {1421-9727},
  keyword      = {lung function testing,in preterm infants,NAC treatment,N-acetylcysteine treatment,antioxidant defense system,bronchopulmonary dysplasia},
  language     = {eng},
  number       = {4},
  pages        = {275--279},
  publisher    = {Karger},
  series       = {Biology of the Neonate},
  title        = {N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants},
  url          = {http://dx.doi.org/10.1159/000080089},
  volume       = {86},
  year         = {2004},
}